Sapient Capital LLC Boosts Holdings in Intuitive Surgical, Inc. (NASDAQ:ISRG)

Sapient Capital LLC grew its position in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 2.1% in the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 97,736 shares of the medical equipment provider’s stock after buying an additional 2,002 shares during the quarter. Intuitive Surgical accounts for 1.0% of Sapient Capital LLC’s investment portfolio, making the stock its 19th largest holding. Sapient Capital LLC’s holdings in Intuitive Surgical were worth $48,015,000 at the end of the most recent reporting period.

Other hedge funds also recently made changes to their positions in the company. Able Wealth Management LLC purchased a new position in Intuitive Surgical in the fourth quarter worth $28,000. GLOBALT Investments LLC GA acquired a new stake in shares of Intuitive Surgical in the fourth quarter valued at about $304,000. Integrated Advisors Network LLC grew its position in Intuitive Surgical by 6.3% during the fourth quarter. Integrated Advisors Network LLC now owns 1,598 shares of the medical equipment provider’s stock worth $539,000 after buying an additional 95 shares during the period. Centaurus Financial Inc. increased its holdings in Intuitive Surgical by 12.2% in the fourth quarter. Centaurus Financial Inc. now owns 2,183 shares of the medical equipment provider’s stock valued at $737,000 after buying an additional 238 shares in the last quarter. Finally, SageView Advisory Group LLC lifted its position in shares of Intuitive Surgical by 619.1% during the 4th quarter. SageView Advisory Group LLC now owns 4,926 shares of the medical equipment provider’s stock valued at $1,662,000 after acquiring an additional 4,241 shares during the period. Institutional investors and hedge funds own 83.64% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on the company. BTIG Research raised their price objective on Intuitive Surgical from $469.00 to $494.00 and gave the company a “buy” rating in a research note on Wednesday, August 28th. Truist Financial lifted their price target on Intuitive Surgical from $450.00 to $515.00 and gave the stock a “buy” rating in a research note on Tuesday, July 16th. Evercore ISI raised their target price on shares of Intuitive Surgical from $410.00 to $475.00 and gave the company an “in-line” rating in a report on Tuesday, October 1st. Redburn Atlantic upgraded shares of Intuitive Surgical from a “neutral” rating to a “buy” rating and increased their price target for the company from $380.00 to $510.00 in a research report on Friday, August 2nd. Finally, Barclays lifted their price objective on Intuitive Surgical from $430.00 to $490.00 and gave the stock an “overweight” rating in a research report on Thursday, July 18th. Six investment analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $458.35.

Insider Activity at Intuitive Surgical

In other Intuitive Surgical news, Director Amy L. Ladd sold 450 shares of the business’s stock in a transaction that occurred on Friday, September 13th. The shares were sold at an average price of $490.28, for a total transaction of $220,626.00. Following the completion of the sale, the director now directly owns 821 shares in the company, valued at $402,519.88. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In other news, Director Amy L. Ladd sold 450 shares of the company’s stock in a transaction dated Friday, September 13th. The stock was sold at an average price of $490.28, for a total value of $220,626.00. Following the completion of the sale, the director now owns 821 shares of the company’s stock, valued at $402,519.88. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Robert Desantis sold 1,413 shares of the firm’s stock in a transaction dated Friday, July 26th. The shares were sold at an average price of $438.60, for a total value of $619,741.80. Following the sale, the executive vice president now owns 5,506 shares in the company, valued at approximately $2,414,931.60. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 53,120 shares of company stock worth $25,528,753. Company insiders own 0.90% of the company’s stock.

Intuitive Surgical Stock Up 0.2 %

Shares of ISRG opened at $485.69 on Monday. The firm has a market cap of $172.27 billion, a PE ratio of 87.51, a price-to-earnings-growth ratio of 5.40 and a beta of 1.39. The company’s fifty day moving average is $480.34 and its two-hundred day moving average is $435.19. Intuitive Surgical, Inc. has a fifty-two week low of $254.85 and a fifty-two week high of $496.48.

Intuitive Surgical (NASDAQ:ISRG) last announced its quarterly earnings results on Thursday, July 18th. The medical equipment provider reported $1.78 EPS for the quarter, topping the consensus estimate of $1.54 by $0.24. The company had revenue of $2.01 billion during the quarter, compared to analyst estimates of $1.97 billion. Intuitive Surgical had a return on equity of 13.04% and a net margin of 27.65%. The firm’s revenue was up 14.5% on a year-over-year basis. During the same period in the prior year, the firm posted $1.18 earnings per share. As a group, equities research analysts anticipate that Intuitive Surgical, Inc. will post 5.22 earnings per share for the current year.

Intuitive Surgical Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.